Broker gives its verdict on the Ramsay Health Care (ASX:RHC) share price

Is the Ramsay share price in the buy zone?

| More on:
A doctor in a white coat with a stethoscope around his neck stands in the hallway of a hospital deep in concentration over a tablet device in his hands.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited (ASX: RHC) share price came under pressure on Thursday.

The private hospital operator's shares fell 4% to $69.38.

Why did the Ramsay Health Care share price fall?

Investors were selling down the Ramsay Health Care share price following the release of a trading update.

That update revealed a decent 1.3% increase in unaudited first quarter revenue to $3.2 billion, but a 39.5% decline in unaudited quarterly profit after tax to $58.1 million.

This was driven by the impacts of elective surgery restrictions and disruptions caused by isolation orders and lockdowns across Australia.

Is it time to buy?

One leading broker that sees value in Ramsay Health Care's shares following their decline is Goldman Sachs.

According to a note from this morning, the broker has reiterated its buy rating and $74.00 price target on the company's shares.

Based on the Ramsay Health Care share price, this implies potential upside of almost 7% for investors. This potential return stretches to almost 9% if you include dividends.

What did the broker say?

While the broker acknowledges that trading conditions will remain challenged for a little while longer, it believes Ramsay is well-placed to bounce back strongly in 2022.

Goldman commented: "Whilst operating performance will remain challenged in 2Q22, we see scope for much stronger operating conditions to manifest from early-2022: 1) elevated utilisation profile (backlog-assisted and catalysed by reduction/removal of remaining surgery restrictions): 2) improving cost absorption (two-thirds of costs are fixed); 3) tapering of cash 'covid costs' (GSe: 5-10% of pre-Covid EBIT currently); 4) improving sales mix (non-surgical); and 5) improving surgical mix (higher-acuity)."

The broker also highlights that the Ramsay Health Care share price is trading on attractive multiples and sees scope for a rerating in the future.

It concluded: "The stock is trading at 8.7x EBITDA for a +7% EBITDA CAGR (FY21-24E), towards the bottom of its 5-year range. We believe the strong potential for improvement in near-term fundamentals is still not reflected in consensus forecasts or current trading multiples. We reiterate our Buy rating and $74 12-month Target Price."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Four people on the beach leap high into the air.
Broker Notes

4 ASX All Ords shares offering 10% to 30% annual growth: brokers

These ASX All Ords stocks have caught the eye of brokers this week.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Here are 2 ASX shares that Morgans rates as buys

Let's see why the broker is feeling bullish on these stocks.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Broker Notes

Guess which ASX 200 stock was just upgraded to a buy rating

Why did the broker just turn bullish? Let's find out.

Read more »

Two brokers analysing stocks.
Broker Notes

Don't miss these changes to broker ratings on ASX shares

The verdicts are in.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these stocks.

Read more »

man thinking about whether to invest in bitcoin
Broker Notes

Why now is the time to buy this beaten down $8b ASX 200 stock

Goldman Sachs thinks that now is the time to invest in this beaten down drinks giant.

Read more »

a man sits alone in his house with a dejected look on his face as he looks at a glass of red wine he is holding in his hand with an open bottle on the table in front of him.
Broker Notes

Red alert! 4 ASX All Ords shares just got broker downgrades

These ASX All Ords stocks have caught the attention of brokers for all the wrong reasons.

Read more »